Loading company…
Sichuan Zhishan Weixin Biotechnology develops original gene therapy drugs based on rAAV vectors, based in Chengdu, China.
Sichuan Zhishan Weixin Biotechnology develops original new drugs for rAAV gene therapy, with a pipeline covering hematology, central nervous system and metabolic indications. Its first self-developed product, ZS801 for hemophilia B, received clinical approval in August 2022. Founded in 2018 in Chengdu, China, the company's founder, Prof. Biao Dong, has long worked in rAAV research, and the company raised series B+ funding in December 2025 from Chengdu Science and Technology Venture Capital Group and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in